These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 3808229)

  • 1. Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs.
    Morita J; Yuge K; Yoshino M
    Neuropediatrics; 1986 Nov; 17(4):203-5. PubMed ID: 3808229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
    Coppola G; Epifanio G; Auricchio G; Federico RR; Resicato G; Pascotto A
    Brain Dev; 2006 Jul; 28(6):358-65. PubMed ID: 16376041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vigabatrin, lamotrigine, topiramate and serum carnitine levels.
    Zelnik N; Isler N; Goez H; Shiffer M; David M; Shahar E
    Pediatr Neurol; 2008 Jul; 39(1):18-21. PubMed ID: 18555168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and muscle carnitine levels in epileptic children receiving sodium valproate.
    Anil M; Helvaci M; Ozbal E; Kalenderer O; Anil AB; Dilek M
    J Child Neurol; 2009 Jan; 24(1):80-6. PubMed ID: 19168820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The association of hypocarnitinemia with enteral diets and antiepileptic drugs in children and adults with severe physical and mental disabilities].
    Wakisaka A; Niida Y; Yamada S; Tsuji T; Nakamura N; Maruhashi K; Ohno I; Seki H
    No To Hattatsu; 2013 Nov; 45(6):445-50. PubMed ID: 24313004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the effect of long term valproic acid treatment on plasma levels of carnitine, ammonia and amino acids related to the urea cycle in pediatric epileptic patients].
    Navarro-Quesada FJ; Lluch-Fernández MD; Vaquero-Abellán M; Marchante-Serrano C; Jiménez C
    Rev Neurol; 1997 Jul; 25(143):1037-44. PubMed ID: 9280630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiepileptic drug polytherapy on crystalluria.
    Go T
    Pediatr Neurol; 2005 Feb; 32(2):113-5. PubMed ID: 15664771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for sodium valproate-induced renal tubular dysfunction.
    Koga S; Kimata T; Yamanouchi S; Tsuji S; Yoshimura K; Araki A; Kaneko K
    Clin Exp Nephrol; 2018 Apr; 22(2):420-425. PubMed ID: 28836089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypocarnitinemia in patients affected by a primary defect of ammonia metabolism treated with sodium benzoate].
    Michalak A; Lambert MA; Dallaire L; Melançon SB; Laframboise R; Lemieux B; Qureshi IA
    Diabete Metab; 1990; 16(3):226-33. PubMed ID: 2210018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium valproate: dose-plasma level relationships and interdose fluctuations.
    Vajda FJ; Mihaly GW; Miles JL; Morris PM; Bladin PF
    Clin Exp Neurol; 1978; 15():145-53. PubMed ID: 386306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carnitine deficiency and L-carnitine supplementation in lysinuric protein intolerance.
    Tanner LM; Näntö-Salonen K; Rashed MS; Kotilainen S; Aalto M; Venetoklis J; Niinikoski H; Huoponen K; Simell O
    Metabolism; 2008 Apr; 57(4):549-54. PubMed ID: 18328359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiepileptic drugs and carnitine].
    Campistol J; Chávez B; Vilaseca MA; Artuch R
    Rev Neurol; 2000 Jun; 30 Suppl 1():S105-9. PubMed ID: 10904975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium valproate -- induced skeletal myopathy.
    Kasturi L; Sawant SP
    Indian J Pediatr; 2005 Mar; 72(3):243-4. PubMed ID: 15812121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valproate-induced hyperacute hyperammonemic coma in a patient with hypocarnitinemia.
    Sofi A; Herial NA; Ali II
    Am J Ther; 2013; 20(6):e703-5. PubMed ID: 20224318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Certain aspects of interaction between sodium valproate and other anticonvulsant drugs in the therapy of epilepsy in children.
    Sobaniec W
    Mater Med Pol; 1992; 24(2):115-9. PubMed ID: 1307765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet.
    Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Mann JI
    Bipolar Disord; 2006 Oct; 8(5 Pt 1):503-7. PubMed ID: 17042889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.